原料药 API
具备 GMP / DMF 注册就绪度的原料药（API）与候选药物 · 每条标明用途、适应症与为何值得上线
Listing Logic · Why These Products
This category is not a mere directory listing—each product is selected against the four criteria below and comes with both its 'use' and 'why it is listed' so buyers can quickly assess fit. Products are drawn from Unibest's API & Candidates supply catalog and posted after dual qualification and demand screening.
We prioritize APIs already GMP/DMF-ready that can directly support regulatory filing, avoiding the compliance cost of building from scratch.
We target chronic long-term therapies, (WHO) public-health procurement and specialty must-have scenarios with low, predictable demand volatility.
We include first-in-class mechanisms, first approvals or molecules addressing resistance/unmet need, offering differentiated pricing power.
We also tag the number of linked intermediates—deeper in-house intermediate coverage means higher feasibility for scale-up and cost reduction.
Browse by Indication
Pick a class to see only APIs for that disease areaDiabetes, obesity, dyslipidemia, NASH and other metabolic diseases
Hypertension, heart failure, anticoagulation, chronic kidney disease
Solid tumours, haematologic malignancies, myeloproliferative diseases
Antiviral, antibacterial, antifungal, HIV / hepatitis
RA, psoriasis, atopic dermatitis, IBD
Epilepsy, pain, depression & anxiety, neurodegeneration
Acid-related, GI motility, diarrhoea, liver disease
COPD, asthma and other airway diseases
Menopausal symptoms, urological conditions
Glaucoma, ocular surface disease
Skin infection, dermatologic inflammation
Local anaesthesia, postoperative analgesia
Allergic rhinitis, urticaria
Companion-animal ectoparasiticides
Browse by Patent Expiry
The cliff decides when to act — filter by window firstCompound patent expired — generic sourcing and registration feasible
Cliff approaching — lock in API supply and filing schedule early
Mid-term opportunity — start process development and DMF work
Still on-patent — typically licensing or clinical supply
No expiry on file — request a patent assessment for this molecule
Expiry years are compiled from public sources and estimated on compound patents in major markets (US / EU). They exclude polymorph, process and formulation patents, term extensions and paediatric exclusivity. Values marked indicative are directional; values marked to-verify are inferred from filing era. Actual generic entry timing depends on national patent offices and the Orange Book.
Letermovir
Prophylaxis of cytomegalovirus (CMV) infection in adult recipients of allogeneic hematopoietic stem cell transplant
A first-in-class CMV terminase inhibitor replacing older ganciclovir-class agents with a better safety profile; a niche, high-value specialty API with limited competition.
- CAS
- 917389-32-3
- Therapeutic Area
- Anti-infective / Transplant
- Labeled Purity
- 98%+
- Patent scope
- US / EU compound patent
Baloxavir Marboxil
Single-dose oral treatment and post-exposure prophylaxis of influenza A and B
A novel single-oral-dose influenza agent with concentrated seasonal demand; integrated API-to-finished supply is attractive for regional pandemic stockpiling.
- CAS
- 1985606-14-1
- Therapeutic Area
- Anti-infective / Antiviral
- Labeled Purity
- 98%+
- Patent scope
- Compound patent in major markets
Ozenoxacin
Topical treatment of superficial skin bacterial infections such as impetigo
A topical non-fluoroquinolone quinolone targeting resistant Gram-positive bacteria; its pediatric and local-use profile offers differentiation in OTC and pediatric markets.
- CAS
- 245765-41-7
- Therapeutic Area
- Anti-infective / Dermatology
- Labeled Purity
- 98%+
Zoliflodacin
Uncomplicated gonorrhea, especially resistant Neisseria gonorrhoeae
An oral single-dose agent with a wholly new mechanism against antimicrobial-resistant gonorrhea, a WHO-priority AMR direction with clear public-health procurement demand.
- CAS
- 1620458-09-4
- Therapeutic Area
- Anti-infective / Resistant Bacteria
- Labeled Purity
- 98%+
Vapendavir
Rhinovirus infection, to reduce acute exacerbations in asthma/COPD patients
A capsid-binding inhibitor of rhinovirus that can reduce hospitalizations from COPD/asthma exacerbations, a scarce causal-therapy attempt in respiratory care.
- CAS
- 439085-51-5
- Therapeutic Area
- Anti-infective / Respiratory
- Labeled Purity
- 98%+
Itarnafloxin
Antibacterial treatment of bacterial infectious diseases
A broad-spectrum fluoroquinolone with extensive clinical experience and controllable cost, suited as a mature generic supply for regional markets.
- CAS
- 865311-47-3
- Therapeutic Area
- Anti-infective
- Labeled Purity
- 98%+
Islatravir
Treatment of HIV-1 infection and long-acting pre-exposure prophylaxis (PrEP)
A novel nucleoside reverse-transcriptase translocation inhibitor (NRTTI) with long-acting dosing, the core evolution of HIV treatment and prevention, high strategic value.
- CAS
- 865363-93-5
- Therapeutic Area
- Anti-infective / HIV
- Labeled Purity
- 98%+
Isavuconazole
Invasive aspergillosis and mucormycosis (deep fungal infections)
A broad-spectrum triazole covering both aspergillus and mucor, for critical deep fungal infections in immunocompromised patients, an ICU/hematology must-have replacing amphotericin B.
- CAS
- 241479-67-4
- Therapeutic Area
- Antifungal
- Labeled Purity
- 99%+
- Patent scope
- US / EU compound patent
Bemnifosbuvir Sulfate
Treatment of hepatitis C virus (HCV) infection
An NS5B nucleotide analog with pangenotypic activity and a high resistance barrier, an important component of HCV combination and retreatment regimens.
- CAS
- 2241337-84-6
- Therapeutic Area
- Antiviral / Hepatitis
- Labeled Purity
- 98%+
Abacavir hydroxyacetate
Antiretroviral combination therapy for HIV-1 infection
A classic nucleoside reverse-transcriptase inhibitor still anchoring AIDS cocktail therapy; long-term must-have in national public-health procurement.
- CAS
- 1446418-48-9
- Therapeutic Area
- Anti-infective / HIV
- Labeled Purity
- 98%+
- Patent scope
- Compound patent long expired; mature multi-source generic supply
Tedizolid Phosphate
Acute bacterial skin and skin-structure infections (including MRSA)
A next-generation oxazolidinone with once-daily dosing and lower myelosuppression risk than peers, an important option against resistant Gram-positive bacteria.
- CAS
- 856867-55-5
- Therapeutic Area
- Anti-infective / Resistant Bacteria
- Labeled Purity
- 99%+
Supply source: Unibest API & Candidates supply catalog, sourced and delivered by Unibest. Therapeutic area, indication and selection rationale are qualitative summaries based on public drug knowledge for business reference; actual registration availability is subject to DMF/GMP documentation and the technical agreement confirmed at order.